Compare SGHC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | ADMA |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | N/A | N/A |
| Metric | SGHC | ADMA |
|---|---|---|
| Price | $10.47 | $17.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $16.00 | ★ $28.50 |
| AVG Volume (30 Days) | 2.0M | ★ 2.0M |
| Earning Date | 02-24-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 4925.62 | 205.35 |
| EPS | 0.45 | ★ 0.86 |
| Revenue | ★ $2,342,912,011.00 | $488,559,000.00 |
| Revenue This Year | $28.87 | $22.19 |
| Revenue Next Year | $10.07 | $23.71 |
| P/E Ratio | $23.18 | ★ $20.97 |
| Revenue Growth | ★ 34.94 | 27.63 |
| 52 Week Low | $5.45 | $13.50 |
| 52 Week High | $14.38 | $25.67 |
| Indicator | SGHC | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 43.36 |
| Support Level | $11.34 | $17.45 |
| Resistance Level | $12.04 | $18.95 |
| Average True Range (ATR) | 0.46 | 0.59 |
| MACD | -0.15 | -0.22 |
| Stochastic Oscillator | 9.90 | 18.47 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.